Oncology tops $84B, Mounjaro surges 124%: Your guide to the 2025 pharma landscape. FY2024 reset the competitive landscape in pharma. While oncology held its top sales standing, the rapid ascent of GLP-1s, market erosion from Humira biosimilars, and the advance of new modalities revised the new biopharma hierarchy. This deep-dive report builds on the Pharma…